Celgene International Sàrl announced that the Intergroupe Francophone du Myelome and University Hospital of Toulouse, the sponsor of the study, reported that the independent Data and Safety Monitoring Committee, of the international phase-III, randomized, double-blind, multi-centre clinical study (IFM 2005 02) evaluating Revlimid (lenalidomide) compared to placebo in multiple myeloma patients following autologous stem cell transplant, has reviewed a preplanned interim analysis and indicated that the primary endpoint of the study has been met. Patients receiving Revlimid demonstrated superior progression-free survival compared to those who received placebo.

Further results from the study will be presented at a major medical meeting in 2010.

The IFM data are from an investigational study. Revlimid does not have marketing approval for the treatment of patients with newly diagnosed multiple myeloma.

Revlimid is an IMiDs compound. Revlimid and other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents.